Kezdőlap・Részvénylista・Danaher Corp

Danaher Corp

Lezárt

SzektorEgészségügy

194.61 -1.46

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

192.43

Maximum

199.67

Fő mutatók
By Trading Economics
Bevétel	-159M 870M
Értékesítés	314M 6.3B
P/E Szektor átlag	35.027 64.641
Egy részvényre jutó nyereség	1.94
Osztalékhozam	0.75
Profit margin	13.887
Munkavállalók	58,000
EBITDA	-364M 1.1B

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+11.28% upside

Osztalékok
By Acuity
Osztalékhozam Szektor átlag	0.75% 2.31%
Következő eredményjelentés	2026. okt. 20.
Következő osztalékfizetési dátum	2026. okt. 30.
Következő korábbi osztalék dátum	2026. szept. 25.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-4.2B 138B
Előző nyitás	196.07
Előző zárás	194.61

Hangulat hírek alapján

By Acuity

50%

151 / 340 Rangsor szerint Healthcare

Danaher Corp Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 3. 22:51 UTC

News

Danaher Corp appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026. Shares are trading higher in after-market hours.

2026. júl. 31. 23:01 UTC

Danaher Corp shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market weakness.

2026. júl. 30. 18:01 UTC

Danaher Corp. shares are lower today, fluctuating within their one-month range amid volatility influenced by the Federal Reserve's interest rate decisions.

2026. júl. 29. 23:01 UTC

Danaher Corp shares are higher in after-market trading, reflecting a slight increase since Wednesday's close. The stock reached a recent high shortly after 5:10 PM ET.

2026. júl. 28. 23:01 UTC

Danaher Corp shares declined in after-hours trading amid broader market losses linked to concerns over artificial intelligence spending and competition from Chinese chipmakers.

2026. júl. 27. 23:16 UTC

Danaher Corp shares are lower in after-market trading, declining slightly since Monday's close. No specific company news has been identified to explain the movement.

2026. júl. 24. 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

2026. júl. 23. 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

2026. júl. 22. 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

2026. júl. 21. 19:41 UTC

News

Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

2026. júl. 20. 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Társak összehasonlítása

Árváltozás

Danaher Corp Előrejelzés

Célár

By TipRanks

11.28% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 219.78 USD 11.28%

Magas 240 USD

Alacsony 195 USD

20 Wall Street elemző 12 hónapos célárain alapulva a(z)Danaher Corp termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

20 ratings

Vétel

Tartás

Eladás

20 Wall Street elemző célárain alapulva a(z)Danaher Corp termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

151 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.